Topics:

Leukemia & Lymphoma

Ibrutinib Yields Durable Responses in CLL

Monotherapy with the investigational oral Bruton's tyrosine kinase inhibitor ibrutinib was well tolerated and produced durable responses in a phase Ib/II, open-label, multicenter study of 85 patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Leukemia & Lymphoma

Data from a pooled analysis show that PET-CT provided better response assessment than did CT and predicted inferior survival in follicular lymphoma patients.

Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy have an increased risk of developing diabetes mellitus, says a new study.

A study of more than 4,500 patients with acute myeloid leukemia (AML) found that predicting resistance to therapy remains an elusive practice.

The rationale for maintenance therapy in indolent non-Hodgkin lymphoma was derived from historical data suggesting that despite robust response rates to standard therapy, most patients eventually relapse and disease-free intervals become progressively shorter.

While definitions of follicular lymphoma maintenance therapy in clinical trials and clinical practice have been somewhat variable, ideally maintenance therapy would be limited to patients in complete remission or with minimal residual disease following initial therapy

STAT3 inhibition using a novel compound restored sensitivity to TKIs in CML cells that had shown resistance independent of BCR-ABL1 kinase activity.

A laboratory study found that natural killer cells could be multiplied from the blood of patients to fight off precursor B-lineage acute lymphoblastic leukemia.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.